Peptide News

A static news aggregator refreshed from FDA MedWatch, PubMed, and ClinicalTrials.gov so the site can surface real signal without inventing headlines.

Latest sync: Mar 17, 2026, 1:24 AM. This page favors official and public primary sources over generic news scraping.

FDA safety feed

Status: live

PubMed research watch

Status: live

ClinicalTrials.gov updates

Status: live

FDA.gov FDA Press Releases

FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s

The U.S. Food and Drug Administration today announced the issuance of 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products offered on their websites.

glp-1compounded

13 days ago 2026-03-03T18:29:38.000Z

FDA.gov FDA Press Releases

FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs

Today, the U.S. Food and Drug Administration is announcing its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies

Peptide News

FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s

FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Retatrutide in type 2 diabetes mellitus and obesity: an overview.

Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight

A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes

Tirzepatide in MetALD

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer

Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A Review.

Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes.

Stable Gastric Pentadecapeptide BPC 157 as a Therapy of Severe Electrolyte Disturbances in Rats.

Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury

GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV

Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass

Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons

Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK.

A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.

Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk

Targeting the LPI/GPR55 Axis in MAFLD and MASH: Novel Insights, Therapeutic Strategies and Future Directions.

Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis.

Factors influencing patient preferences for obesity pharmacotherapy: The triangulation of semi-structured interviews, photovoice study and focus group discussions.

Calculating cost per event avoided using a composite number needed to treat.

Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov.

FDA.gov

ClinicalTrials.gov

PubMed